Apollo Management Holdings’s Calidi Biotherapeutics CLDI Stock Holding History

Apollo Management Holdings’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$249	Hold	1,042	–	–	﹤0.01%	86
2025 Q4	$1.22K	Hold	1,042	–	–	﹤0.01%	107
2025 Q3	$1.58K	Buy	+1,042	New	+$4.42K	﹤0.01%	52
2025 Q2	–	Sell	-1,042	Closed	-$7.08K	–	54
2025 Q1	$7.08K	Hold	1,042	–	–	﹤0.01%	48
2024 Q4	$14.4K	Hold	1,042	–	–	﹤0.01%	48
2024 Q3	$14.3K	Buy	+1,042	New	+$18.1K	﹤0.01%	42
2024 Q2	–	Sell	-1,042	Closed	-$70.6K	–	55
2024 Q1	$70.6K	Buy	+1,042	New	+$106K	﹤0.01%	53
2022 Q3	–	Sell	-9,900	Closed	-$11.8M	–	247
2022 Q2	$11.8M	Sell	9,900 -6,229	-39%	-$7.42M	0.08%	68
2022 Q1	$19.1M	Sell	16,129 -371	-2%	-$438K	0.09%	76
2021 Q4	$19.4M	Buy	+16,500	New	+$19.4M	0.08%	47

Other funds holding CLDI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Apollo Management Holdings's CLDI Position: Q1 2026 in Review

Apollo Management Holdings held its Calidi Biotherapeutics (CLDI) position steady in Q1 2026 at 1,042 shares worth $249. The position accounts for ﹤0.01% of the portfolio, ranked #86.

Apollo Management Holdings first reported a position in CLDI in Q4 2021 and has held it in 10 quarters since. The position peaked at $19.4M in Q4 2021. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

Apollo Management Holdings held 1,042 shares of Calidi Biotherapeutics worth $249 as of Q1 2026.
Apollo Management Holdings left its Calidi Biotherapeutics share count unchanged in Q1 2026.
Calidi Biotherapeutics made up ﹤0.01% of Apollo Management Holdings's portfolio in Q1 2026, its #86 holding.
Apollo Management Holdings first reported a position in Calidi Biotherapeutics in Q4 2021 and has held it in 10 quarters since.
Apollo Management Holdings's Calidi Biotherapeutics position peaked at $19.4M in Q4 2021.
28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Apollo Management Holdings's 13F filing for Q1 2026, filed 15 May 2026.